Ultragenyx Pharmaceuticals Release: Sialic Acid Extended-Release Phase 2 Study Data To Be Presented At American Academy of Neurology Annual Meeting

Published: Apr 28, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NOVATO, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the upcoming presentation of data from a Phase 2 clinical study of sialic acid extended-release (SA-ER, UX001) tablets in hereditary inclusion body myopathy (HIBM; also known by its new name as GNE myopathy). HIBM is a rare, progressive muscle-wasting disease, and SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM.

Help employers find you! Check out all the jobs and post your resume.

Back to news